Article
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. Highlights include referral rules, combination biiologics in psoriasis and don't use JAK inhibitors in pregnancy.
All News
Article
“Orthopedics or rheumatology, who should I see?" A question, often asked with urgency, posed by those who genuinely don’t know who to see for a musculoskeletal (MSK) complaint. Inquiring patients, family, or other physicians may be one forum for such a request. Another occurs in the hospital and clinic when referrals for MSK issues can go in either direction. How would you guide such requests? And what would your answers be based on?
Article
Today Lilly announced top line results of the TOGETHER-PsO open-label, Phase 3b trial demonstrating the significant benefits of concomitant ixekizumab (IXE: an IL-17A inhibitor) and tirzepatide (TIR: GLP-1agonist) over IXE alone.
Article
The notion of intervening in autoimmune disease prior to the onset of irreversible tissue damage has evolved beyond a theoretical framework; it is presently undergoing empirical evaluation. Recent discussions on incomplete lupus and the SMILE trial, alongside advances in Sjögren’s therapeutics, highlight both the promise and complexity of prevention and precision treatment in systemic autoimmunity.
Article
Dr. Arthur Kavanaugh and Dr. Eric Ruderman gave an update on what's new in spondyloarthritis at the 2026 Rheumatology Winter Clinical Symposium (RWCS) in Maui, Hawaii. Here's a summary.
Dr. John Cush
Tweet
The vasculitis session at #RNL26 was a fantastic update on inflamed blood vessels, large and small, by two experts in the field.
https://t.co/KuVei8jiFu https://t.co/47cI4WSSkU
American College of Rheumatology
Tweet
New studies posted this week in Arthritis & Rheumatology:
Adalimumab ± MTX as first-line therapy for childhood-onset chronic uveitis
https://t.co/L4QiZZBBG7
Bisphosphonates & PPI/H2RA coprescriptions in polymyalgia rheumatica
https://t.co/62Pqt5Ab58
Phase 3b SOLSTICE trial: https://t.co/MsK4XC3eNh
Eric Topol
Tweet
You gotta be kidding me
@mims
gift link
https://t.co/wf9kLhSu8a https://t.co/jB3ZYyB549
Dr. John Cush
Tweet
Population survey of 21 000 US adults, 62.3% reported recent use of any OTC or prescription meds. Past-7-day prevalence of any OTC medication was equal to RX med use (46%) and increased use with age among both male and female individuals. https://t.co/xeWBQ0DnlB https://t.co/c8lqXOmAaT
Dr. John Cush
Tweet
Comorbidity & Health Management
https://t.co/cSwCEDKL28 https://t.co/WP7yIdWPVY
Dr. John Cush
Tweet
UK Biobank registry analyzed assoc. betw sleep duration, insomnia, & shift with osteoarthritis endpoints (KOA, HOA, TKA, THA) - all incr/highest in pts w/ <6 hrs nightly sleep. Night shift workers had 24% higher knee OA risk (HR=1.24) & 28% higher TKA risk (HR=1.28). https://t.co/UnxXH2I92R
Dr. John Cush
Tweet
RT @richardPAConway
The new kid on the block in RA-ILD (and other PPF). Nerandomilast, an anti-fibrotic with additional anti-inflammatory/immunomodulating functions. Demonstrated significant mortality benefit in ILD. #RNL26 https://t.co/8DU3WyPQGy
Dr. John Cush
Tweet
RT @ericdeinMD
#RNL26
Prosthetic joint infection vs flare?
- PJI risk 50-80% higher in RA (OR 1.47-1.8)
- Immunosuppressants, intra-artic injections, RA activity, BMI incr risk
- Delay in diagnosis https://t.co/XTozafDQyf
Dr. John Cush
Tweet
Spectrum of skin Sxs in 518 pts w/ Stills dz from AutoInflammatory Dz Alliance (AIDA) Network Registry dedicated to Still’s disease includes Salmon evanescent rash (64%), macules (7.7%), urticaria (6%), persistent pruritic papules & plaques (PPPP) (4.8%) https://t.co/DW9NoaxNPP https://t.co/U5GrCutYT0
Dr. John Cush
Tweet
Maui Potpourri (2.13.2026)
Dr. Jack Cush reviews the hot item takeaways from last week's RheumNow Live 2026.
https://t.co/ieRhIVZb2D https://t.co/KaYtSnHUIL
Dr. John Cush
Tweet
Rotator cuff abnormalities are nearly universal after age 40, & incr w/ age; routine imaging should not guide Dz or Tx of atraumatic shoulder pain. Study of 602 having MRI (58yrs) RC abnormalities in 98.7%;; 25% tendinopathy, 62% Partial & 11% Full thickness tears https://t.co/Jw9rMUQBLs
Dr. John Cush
Tweet
RT @ericdeinMD
#RNL26
Arthroplasty risks in RMD
AxSpA - Respiratory complications (OR 1.7), PNA (2.2)
SLE - complications ass w/ severity/activity. Renal failure, PE, sepsis, stroke, mortality depending on activity
PsA - complications related to co-morbidities, not PsA https://t.co/jr0hwh3CPe
Dr. John Cush
Tweet
RNL 26 Report: Spondyloarthritis
Audrey Gibson, PA-C, reports from RheumNow Live 2026 in Dallas, Texas, about lectures presented during the "Staying Ahead of Spondyloarthritis" session.
https://t.co/UjvauWoga5 https://t.co/Zv8dmUuVyD
Dr. John Cush
Tweet
Obesity, Surgery, and Optimizing Patient Care
Rheumatologic care requires a multidisciplinary approach and collaboration with other specialties to treat complex systemic diseases. While many Pods at RheumNow Live are disease-specific, the Pod II focused on Advancing Practice on https://t.co/hvSY5yHZmd
Dr. John Cush
Tweet
The vasculitis session at #RNL26 was a fantastic update on inflamed blood vessels, large and small, by two experts in the field.
https://t.co/KuVei8jiFu https://t.co/PR4h2qniEL
